Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 117.26M -74.9% |
| Revenue (ttm) | 197.20M -12.4% |
| Net Income | -44.56M |
| EPS | -0.17 |
| Shares Out | 277.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,750,032 |
| Open | 0.4040 |
| Previous Close | 0.4089 |
| Day's Range | 0.3964 - 0.4332 |
| 52-Week Range | 0.3612 - 1.7300 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 2.67 (+531.54%) |
| Earnings Date | Nov 5, 2026 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia... [Read more]
Financial Performance
In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price target is $2.67, which is an increase of 531.54% from the latest price.
News
Akebia granted new patent for Vafseo by USPTO
Akebia (AKBA) announced that a new patent has been granted for Vafseo. The patent, issued by the United States Patent and Trademark Office, or USPTO, is eligible for listing in…
Akebia Therapeutic's Vafseo® (vadadustat) Granted Additional Patent
New patent with term until 2043 further strengthens patent portfolio WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the p...
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
Akebia price target lowered to $2 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Akebia (AKBA) to $2 from $4 and keeps an Overweight rating on the shares. With Q3 reporting largely wrapped up, the firm…
Akebia price target lowered to $4 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Akebia (AKBA) to $4 from $6 and keeps a Buy rating on the shares following the Q3 report.
Akebia price target lowered to $3 from $4 at BTIG
BTIG analyst Julian Harrison lowered the firm’s price target on Akebia (AKBA) to $3 from $4 and keeps a Buy rating on the shares. Vafseo underlying demand remains healthy despite…
Akebia reports topline results from VOCAL trial
Akebia (AKBA) announced topline results from VOCAL, an open-label trial to evaluate the efficacy and safety of three times per week, or TIW, dosing of vadadustat compared to the current…
Akebia Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue declined as Auryxia faced generic pressure and Vafseo inventory fell despite higher patient demand. VOICE outcomes data and upcoming post-TDAPA access may support wider Vafseo use, while rare kidney trials advance.
Akebia Therapeutics Earnings release: Q3 2026
Akebia Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Akebia Therapeutics Quarterly report: Q3 2026
Akebia Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Th...
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful ...
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gr...
Scynexis appoints Burke to Board of Directors
Scynexis (SCYX) announced the appointment of Steven Burke, M.D., to its Board of Directors, effective September 18, 2026. Burke worked at Akebia Therapeutics (AKBA) since 2019.
Akebia doses first patient in ebribafusp trial
Akebia (AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy...
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWI...
Akebia initiated with a Buy at WestPark Capital
WestPark Capital initiated coverage of Akebia (AKBA) with a Buy rating and $4.50 price target
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t...
Akebia downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Akebia (AKBA) to Market Perform from Outperform with a $1 price target
Akebia Therapeutics Earnings Call Transcript: Q2 2026
Vafseo achieved strong revenue and patient growth, driven by positive VOICE trial results and expanded adoption across dialysis organizations. Pipeline assets advanced in rare kidney diseases, while AURYXIA revenues declined due to competition. Cash position supports operations for at least two years.
Akebia Therapeutics Earnings release: Q2 2026
Akebia Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.